Gemcitabine in metastatic breast cancer (Q36185611)

12 August 2017

1 reference

title

Gemcitabine in metastatic breast cancer (English)

1 reference

12 August 2017

1 reference

ChEBI release 2020-05-28

Volker Heinemann

1

1 reference

12 August 2017

publication date

1 June 2005

1 reference

Expert Review of Anticancer Therapy

12 August 2017

published in

1 reference

12 August 2017

volume

5

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

429-443

1 reference

Combination chemotherapy for metastatic breast cancer

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Promising combination therapies with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Single-agent gemcitabine is active in previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Role of capecitabine (Xeloda®) in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Review of recent trials of chemotherapy for advanced breast cancer: studies excluding taxanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer: preliminary results from a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Vinorelbine--a clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Gemcitabine and vinorelbine in pretreated advanced breast cancer: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Phase II trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Phase I/II study of gemcitabine in association with vinorelbine for metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Assessment of hospitalised cancer patients' needs by the Needs Evaluation Questionnaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Gemcitabine and vinorelbine combination in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Platinum-based chemotherapy in metastatic breast cancer: current status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Gemcitabine combined with epirubicin in the treatment of patients with locally advanced or metastatic breast cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.429

21 January 2018

Identifiers

DOI

10.1586/14737140.5.3.429

1 reference

12 August 2017

1 reference